Individualized prophylactic treatment of patients with hemophilia A to improve effectiveness and optimize product consumption on the example of octocog alpha and rurioctocog alpha pegol. A systematic literature review
Open Access
- 13 August 2021
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 22-29
- https://doi.org/10.37489/2588-0519-2021-2-22-29
Abstract
Objective: to review the data on the efficacy and consumption of octocog alfa and rurioctoctog alfa pegol in standard prophylaxis and individualized prophylaxis in hemophilia A patients based on published international data.Material and methods: a systematic literature search and review were performed. Among 25 sources identified within the systematic search 7 relevant sources describing the comparison of treatment with octocog alfa and rurioctocog alfa pegol in adult and pediatric patients with severe and moderate hemophilia A based on personalized assessment of the pharmacokinetic curve using the interactive tool myPKFit versus the standard (non-personalized) dosage regimen were selected. Data on individual patients, as well as data from secondary subgroups defined by age, bleeding rate, risk of bleeding associated with the daily physical activity were combined and analyzed.Results. In observational studies, adjustments of the dose and administration of octocog alfa in patients with severe hemophilia based on personalized assessment of the pharmacokinetic curve using myPKFit resulted in the reduced consumption and/or increased efficacy of prophylaxis — a reduced annual bleeding rate. In an extended controlled study of rurioctocog alpha pegol a trend toward reduced bleeding rate and increased mean annual consumption of the drug was reported in patients who received myPKFit guided prophylaxis compared to a non-personalized treatment regimen. In the single-cut studies, myPKFiT use resulted in the regimen revisions in less than a quarter of patients.Summary. Personalized dosing for octocog alpha and rurioctocog alpha pegol based on pharmacokinetic curve built using pharmacokinetic population model enables reasonable dose adjustments and improves outcomes.Keywords
This publication has 13 references indexed in Scilit:
- Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia AHaemophilia, 2020
- Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia AThrombosis Research, 2019
- Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia AThrombosis Research, 2019
- Individualized approach to profilactic treatment in patients with severe hemophilia ARussian Journal of Children Hematology and Oncology, 2018
- Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic‐guided prophylaxis based on Bayesian models with myPKFiT®Haemophilia, 2018
- PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia AThrombosis Research, 2017
- Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitorsHaemophilia, 2017
- The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia AExpert Opinion on Drug Metabolism & Toxicology, 2016
- Methods for individualising factor VIII dosing in prophylaxisEuropean Journal of Haematology, 2014
- Octocog Alfa (Advate®): A Guide to Its Use in Hemophilia ABioDrugs, 2012